Oncorus Inc (ONCR)

$0.021

Market is closed - opens 8 PM, 05 Dec 2023

Insights on Oncorus Inc

  • Vs SGEN

    In the last 1 year, Seagen, Inc. has given 73.8% return, outperforming this stock by 169.2%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 18.7% return, outperforming this stock by 118.6%

Performance

  • $0.02
    $0.02
    $0.02
    downward going graph

    0.0%

    Downside

    Day's Volatility :4.76%

    Upside

    4.76%

    downward going graph
  • $0.02
    $1.70
    $0.02
    downward going graph

    0.0%

    Downside

    52 Weeks Volatility :98.82%

    Upside

    98.82%

    downward going graph

Returns

PeriodOncorus IncSector (Health Care)Index (Russel 2000)
3 Months
-30.69%
-1.3%
0.0%
6 Months
-81.66%
1.2%
0.0%
1 Year
-95.24%
-5.7%
-6.5%
3 Years
-99.93%
17.1%
-6.5%

Highlights

Market Capitalization
548.0K
Book Value
$1.19
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-3.48
Wall Street Target Price
5.0
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-32.24%
Return On Equity TTM
-124.56%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-69.7M
Diluted Eps TTM
-3.48
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
-0.7
EPS Estimate Next Quarter
-0.61

Analyst Recommendation

Hold
    0
    0%Buy
    57%Hold
    42%Sell
Based on 7 Wall street analysts offering stock ratings for Oncorus Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
00
00
6
Hold
4
5
4
Sell
3
3
00

Analyst Forecast

What analysts predicted

Upside of 23709.52%

Current $0.02
Target $5.00

Technicals Summary

Sell

Neutral

Buy

Oncorus Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Oncorus Inc
Oncorus Inc
0.0%
-81.66%
-95.24%
-99.93%
-99.87%
Moderna, Inc.
Moderna, Inc.
10.77%
-38.07%
-54.62%
-47.66%
329.19%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-2.11%
8.61%
7.86%
65.47%
118.58%
Novo Nordisk A/s
Novo Nordisk A/s
-0.67%
27.21%
58.01%
196.12%
339.58%
Seagen, Inc.
Seagen, Inc.
-0.71%
8.98%
75.48%
18.69%
248.26%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-8.97%
5.01%
10.57%
53.8%
97.36%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Oncorus Inc
Oncorus Inc
NA
NA
NA
0.0
-1.25
-0.32
0.0
1.19
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-11.52
-0.22
-0.07
0.0
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
22.78
22.78
9.01
42.5
0.17
0.09
0.01
234.47
Novo Nordisk A/s
Novo Nordisk A/s
43.04
43.04
2.03
2.62
0.89
0.22
0.01
20.77
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-4.16
-0.28
-0.13
0.03
13.52
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.52
26.52
0.41
15.04
0.23
0.14
0.02
64.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Oncorus Inc
Oncorus Inc
Hold
$3.4M
-99.87%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$29.6B
329.19%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$87.0B
118.58%
22.78
30.47%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$470.4B
339.58%
43.04
35.11%
Seagen, Inc.
Seagen, Inc.
Hold
$40.0B
248.26%
NA
-32.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$91.0B
97.36%
26.52
35.94%

Institutional Holdings

  • Mpm Asset Management, LLC

    10.92%

  • MPM Oncology Impact Management LP

    9.11%

  • CHI Advisors LLC

    9.07%

  • Fosun International Ltd

    3.69%

  • Sphera Funds Management Ltd.

    2.07%

  • Vanguard Group Inc

    1.82%

Corporate Announcements

  • Oncorus Inc Earnings

    Oncorus Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

mpm is an early-stage life sciences venture investing firm with a track record of identifying and building world-class companies that seek to cure major diseases by translating scientific innovations into positive clinical outcomes. mpm’s portfolio of companies aims to revolutionize the face of medicine across multiple areas including cancer, neuroscience, metabolic disorders, and regenerative medicine. with its deep experience, dedicated team of operating executives, and distinguished medical and scientific advisory board, mpm is powering novel medical breakthroughs that transform patient lives.

Organization
Oncorus Inc
Employees
64
CEO
Dr. Mitchell H. Finer Ph.D.
Industry
Health Technology

Discover More

FAQs